Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.
Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal...
MaaT Pharma, a clinical-stage biotech company focused on the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, is now a member of Microbiome Therapeutics Innovation Group (MTIG).
A microbiome therapeutic developed by the Danish biotech company Freya Biosciences has achieved promising topline results in a phase 1 trial in women with asymptomatic vaginal tract dysbiosis.
The microbiome therapeutic developer Vedanta Biosciences has raked in $106.5m to bankroll the launch of a phase 3 trial of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI).
Xbiome Inc, a China headquartered AI-based microbiome therapeutics startup, has acquired the clinical-stage M201 program developed by Assembly Biosciences, a firm developing therapeutics targeting hepatitis B virus and other viral diseases.
Live biotherapeutic product (LBP) developer, 4D Pharma, which has been NASDAQ listed since March this year, has announced positive topline results for the first part of its Phase I/II trial of an LBP strain for the treatment of asthma.
Emulate, Inc recently launched the Zoë-CM2 Culture Module, a second-generation Zoë instrument core to its ‘Organ-on-a-Chip’ based Human Emulation System.
Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...
Insights have been gained into the role of the microbiome in disease states such as cancer, and strategies to manipulate the microbiome are quickly emerging, though optimal approaches are not yet known, said experts during an AACR 2021 event this week....
Californian biotech Siolta Therapeutics has raised $30m in a series B investment round: with the financing to fund the clinical development of novel microbiome-based medicines.
After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
